Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors

JACOPO GIULIANI; ANDREA BONETTI

doi:10.21873/anticanres.13550

Research ArticleClinical Studies

Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors

JACOPO GIULIANI and ANDREA BONETTI

Anticancer Research July 2019, 39 (7) 3961-3965; DOI: https://doi.org/10.21873/anticanres.13550

JACOPO GIULIANI

Department of Oncology, Mater Salutis Hospital, Legnago, Italy

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: jacopo.giuliani{at}aulss9.veneto.it

ANDREA BONETTI

Department of Oncology, Mater Salutis Hospital, Legnago, Italy

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Figures & Data

Tables

PreviousNext

In this issue

Anticancer Research

Vol. 39, Issue 7

July 2019

Table of Contents
Table of Contents (PDF)
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 3 + 0 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors

JACOPO GIULIANI, ANDREA BONETTI

Anticancer Research Jul 2019, 39 (7) 3961-3965; DOI: 10.21873/anticanres.13550

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors

JACOPO GIULIANI, ANDREA BONETTI

Anticancer Research Jul 2019, 39 (7) 3961-3965; DOI: 10.21873/anticanres.13550

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Cited By...

Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
Financial toxicity in patients with lung cancer: a scoping review protocol
Inhibition of Cell-surface Molecular GPR87 With GPR87-suppressing Adenoviral Vector Disturb Tumor Proliferation in Lung Cancer Cells

Google Scholar

Keywords

NSCLC
first-line
second-line
phase III RCTs
pembrolizumab
nivolumab
atezolizumab
cost of drugs

Main menu

User menu

Search

Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors

Article Figures & Data

Tables

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Keywords